GSK plc/£GSK
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
- Ticker
- £GSK
- Sector
- Health
- Primary listing
- LSE
- Employees
- 66,841
- Headquarters
- London, United Kingdom
- Website
- www.gsk.com
GSK plc Metrics
BasicAdvanced
£73B
17.12
£1.07
0.28
£0.68
3.72%
Price and volume
Market cap
£73B
Beta
0.28
52-week high
£22.82
52-week low
£16.90
Average daily volume
6.5M
Dividend rate
£0.68
Financial strength
Current ratio
0.864
Quick ratio
0.554
Long term debt to equity
1.187
Total debt to equity
1.296
Dividend payout ratio (TTM)
62.01%
Interest coverage (TTM)
13.83%
Profitability
EBITDA (TTM)
11,492
Gross margin (TTM)
73.76%
Net profit margin (TTM)
12.97%
Operating margin (TTM)
30.54%
Effective tax rate (TTM)
10.42%
Revenue per employee (TTM)
£500,000
Management effectiveness
Return on assets (TTM)
9.27%
Return on equity (TTM)
28.27%
Valuation
Price to earnings (TTM)
17.118
Price to revenue (TTM)
2.186
Price to book
3.91
Price to tangible book (TTM)
-5.01
Price to free cash flow (TTM)
11.072
Free cash flow yield (TTM)
9.03%
Free cash flow per share (TTM)
1.649
Dividend yield (TTM)
3.72%
Growth
Revenue change (TTM)
4.28%
Earnings per share change (TTM)
-19.72%
3-year revenue growth (CAGR)
4.20%
10-year revenue growth (CAGR)
2.35%
3-year earnings per share growth (CAGR)
-10.33%
10-year earnings per share growth (CAGR)
30.09%
3-year dividend per share growth (CAGR)
7.37%
10-year dividend per share growth (CAGR)
-3.64%
What the Analysts think about GSK plc
Analyst ratings (Buy, Hold, Sell) for GSK plc stock.
Analyst projections of the future price of GSK plc stock.
Bulls say / Bears say
Specialty medicines are driving growth: Q3 sales rose 15%, led by HIV up 10%, respiratory, immunology and inflammation up 21%, and oncology up 23%. GSK reaffirmed its 2026 guidance. (GSK)
The pipeline offers further growth catalysts: GSK reported positive registrational data for lung-cancer drug Ris-Rez and approvals for Hibsago and Jemperli, and is on track to start 22 Phase III trials in 2026. (GSK)
Jideytro’s US approval gives GSK its first foothold in lung cancer, while the acquired Nuvalent portfolio includes another late-stage candidate, neladalkib, under FDA review. This creates an opportunity to build a new oncology business. (GSK)
Vaccine sales weakened in Q3: the segment fell 2%, with Shingrix down 5% and Arexvy down 24%. This could offset growth elsewhere if demand remains soft. (GSK)
Data summarised monthly by Lightyear AI. Last updated on 28 Oct 2026.
GSK plc Financial Performance
Revenues and expenses
GSK plc Earnings Performance
Company profitability
Upcoming events
Funds containing GSK plc
AllEURGBPUSD
Fund name | Fund size | £GSK weighting |
|---|---|---|
iShares MSCI Europe Health Care Sector£ESIH | €940M | 5.11% |
iShares MSCI Europe Health Care Sector€ESIH | €940M | 5.11% |
iShares STOXX Europe 600 Health Care€EXV4 | €729M | 4.88% |
iShares UK Dividend£IUKD | £1.2B | 3.22% |
iShares Edge MSCI Europe Value Factor€CEMS | €2.5B | 3.03% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.